Chemical Proteomics: Drug Targets, Drug Selectivity, MoA and Resistance
Dr. Guillaume Médard, Technische Universität München, speaking at Discovery Chemistry Congress 2013.
Regulation of antibody immunotherapy by fine-tuning FcR interactions
Mark Cragg, Southampton University School of Medicine, speaking at Stem Cells & Bioprocessing 2012.
The Use of -omic Technologies for Biomarker Development
Michael Pfaffl, Principal Investigator, Technical University of Munich, speaking at Genomics Research Asia 2012
Immunogenicity Assessment for the Successful Development of Biosimilars
Dr Michael Tovey, Institut Andre Lwoff/INSERM, speaking at Stem Cells & Bioprocessing 2012.
Bicyclic Peptides with Antibody-Like Binding Affinity and Specificity
Dr Vanessa Baeriswyl, EPFL, speaking at Stem Cells & Bioprocessing Europe 2012.
Drug-induced Hepatotoxicity Prediction Using Three-Dimensional Culture Models in High Content Screening Context
Dr Thierry Dorval, Institut Pasteur Korea, speaking at European Laboratory Automation 2012.
Novel, Simple Technology for Creating Physiologically Relevant 3-D Tissue Models
Rosemary Drake, TAP Biosystems, speaking at European Laboratory Automation 2012.
An Integrated System Using Peptide Arrays to Assess Kinase and Nuclear Receptor Activities in Clinical Samples for Biomarker Development
Bertrand Jordan, Aix-Marseille University, speaking at Microarray World Congress 2012
Phenotypic Drug Screening: the Power of High Capacity Flow
Dr Kim Luu, Intellicyt, Inc., speaking at European Laboratory Automation 2012.